Damora Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapeutics for patients with blood cancers and fibrotic disorders. The company's core research and development pipeline centers on mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms (MPNs), an area of high unmet medical need where uncontrolled cell proliferation causes chronic conditions such as essential thrombocythemia (ET) and myelofibrosis (MF).
The company was originally founded in 2011 as Galecto Biotech AB, an oncology and fibrosis-focused drug developer that went public on Nasdaq in 2020. In November 2025, Galecto completed a transformative asset acquisition of privately held Damora Therapeutics, Inc. along with an associated $285 million private placement. The transaction pivoted the company's focus to an antibody portfolio in-licensed through agreements originating with Paragon Therapeutics. In March 2026, the company rebranded as Damora Therapeutics, Inc. (trading under ticker DMRA), followed by a redomestication from Delaware to the Cayman Islands in July 2026.
Damora's pipeline is headlined by DMR-001, an investigational monoclonal antibody designed to bind both Type 1 and Type 2 mutCALR with high affinity and an extended half-life enabling infrequent subcutaneous dosing. The pipeline also includes DMR-002 and DMR-003, early-stage anti-mutCALR programs designed to address the full spectrum of mutCALR-positive MPNs, as well as legacy asset GB3226, an oral dual inhibitor targeting ENL-YEATS and FLT3 for acute myeloid leukemia. As a clinical-stage development biotech, Damora generates no commercial product revenues and funds operations through equity financings.
